Methylation and Whole-Body Wellness: What You Need to Know

Precision and personalized medicine is gaining traction as it sheds light on how our genes influence health throughout every stage of life. By exploring how our bodies function at a fundamental level, we can develop tailored strategies to address nutrient gaps, enhance metabolism, and unlock performance.

One of the most critical processes in this journey is methylation. Think of it as your body’s way of adding a tiny chemical “tag” (a methyl group, -CH3) to DNA, proteins, or other molecules. In DNA, this often happens at specific spots where cytosine and guanine sit side by side (called CpG sites). This tagging process is a game-changer—it controls which genes are turned on or off, keeps your DNA stable, and ensures your cells function at their best.

Your genes, environment, and lifestyle choices ultimately influence your methylation patterns. We go through life with these patterns, and once they are shattered—that is, when we lose control of our rhythms—we will suffer problems like heart disease, mental disturbances, and chronic fatigue. That's why Methylation is so important to comprehend and support for long-term health.

But methylation is much more than just about genes—it serves as a powerful lifting force throughout your entire body:

• Detox:  Methylation allows your body to accurately excrete and detoxify the chemicals inside, keeping everything running smoothly.
• Mood & Energy: Methylation plays a key role in energy production, helping you feel vibrant and ready to take on the day.
• Mood and Mind:  It helps your body make brain chemicals like serotonin and dopamine that control your feelings, attention, and clarity of thought.

In a nutshell, methylation is your body's high-speed chief executive officer, overseeing everything from energy to detoxing to mood. And, by optimizing this process through diet, lifestyle, and targeted nutrient supplementation, you can take control of your health and unlock your full potential (Andrade et al., 2025; Ménézo et al., 2021)

Personalized Health: The Power of SNPs

SNPs (single nucleotide polymorphisms) are a polymorphism that differs in a single base pair of DNA at certain positions in the genome. SNPs are the most common type of genetic variation among individuals, and they can influence genetic susceptibility to many diseases, responses to drugs, health conditions, and other phenotypic traits. (Kiani et al., 2022)

Though most SNPs are neutral, some can have important functional consequences, such as regulating gene expression or changing the structure and function of proteins. Given their effect on health and their potential to tailor therapeutic recommendations, SNPs are particularly relevant for precision medicine. SNPs found within genes involved in methylation pathways can meaningfully influence the efficiency of these pathways, leading to changes in methylation and downstream health consequences.(Andrade et al., 2025; de Oliveira et al., 2024)

Several SNPs determine the efficiency of methylation pathways. Understanding these genetic variations can lead to an individualized approach to augmenting methylation with targeted dietary and lifestyle changes. These genetic changes are small but can significantly alter the bioavailability of vitamins, minerals, and other nutrients.(Kiani et al., 2022)

Folic acid is an important metabolite and is involved in many metabolic processes, including DNA synthesis and DNA and protein methylation. (Das & Herbert, 1976; Ly et al., 2012) Folate metabolism abnormalities can cause hyperhomocysteinemia (Hcy), a condition known to increase the risk of birth defects, pregnancy-related maternal and fetal complications, vascular and neurodegenerative diseases, diabetes, and neuropsychiatric disorders. (Das & Herbert, 1976; Lajin et al., 2012) 

Specific SNPs in methylation pathways include polymorphisms in the MTHFR gene, such as rs1801133 (C677T) and rs1801131 (A1298C), and the MTRR gene, such as rs1801394 (A66G). The rs1801133 SNP causes an alanine-to-valine substitution at codon 222, resulting in a thermolabile variant of the MTHFR enzyme with reduced activity. This impairment hinders the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a vital step in the methylation cycle.(van der Put et al., 1998) The rs1801131 SNP leads to a glutamate-to-alanine substitution at codon 429, also reducing MTHFR activity, though to a lesser degree than C677T. When both polymorphisms are present together, the reduction in enzyme activity can be further exacerbated.(Das & Herbert, 1976; Lajin et al., 2012) The rs1801394 SNP in the MTRR  gene impacts the regeneration of methionine synthase, an enzyme essential for converting homocysteine back to methionine. When the MTRR function is impaired, it can result in elevated homocysteine levels and disruption of methylation processes. (Ménézo et al., 2021)

 

Hyperhomocysteinemia, or increased levels of homocysteine, is an important indicator of disturbed methylation. Homocysteine, an intermediate in the metabolism of methionine, is normally remethylated back to methionine or transulfurated to cysteine. However, SNPs in MTHFR and MTRR can impair these pathways, leading to elevated levels of homocysteine and increasing the risk of homocysteine-related diseases.(Lajin et al., 2012; Ly et al., 2012)

Decreased MTHFR activity inhibits the conversion of homocysteine to methionine, and peaks of plasma homocysteine are associated with a higher risk of cardiovascular and neurological complications. (de Oliveira et al., 2024)

Tailoring Health with Genetics

Identifying these genetic polymorphisms allows the adoptionof a specific approach to improve methylation with tailored nutrition and lifestyle interventions. These SNP variants can affect the bioavailability of vitamins, minerals, and other nutrients by altering their absorption, transport, storage, and cellular utilization. (Das & Herbert, 1976; Lajin et al., 2012) 

Disruption of metabolic pathways leading to the development of disease is being recognized as most affecting genes from lifestyle and environmental factors (Das & Herbert, 1976; Lajin et al., 2012) This shows the importance of precision and personalized medicine that offers to uncover the genetic predisposition for health from conception to old age. Continuing research into these primary pathways will be critical to developing and tailoring personalized approaches to close nutritional gaps and make metabolism more efficient. (Lajin et al., 2012; Ly et al., 2012)

1. Andrade, P., Santamarina, A. B., de Freitas, J. A., Marum, A. B. R. F., & Pessoa, A. F. M. (2025). Personalized nutrition and precision medicine in perimenopausal women: A minireview of genetic polymorphisms COMT, FUT2, and MTHFR. Clinics (Sao Paulo, Brazil), 80, 100549. https://doi.org/10.1016/j.clinsp.2024.100549
2. de Oliveira, N. F. P., Persuhn, D. C., & Dos Santos, M. C. L. G. (2024). Can Global DNA Methylation Be Influenced by Polymorphisms in Genes Involved in Epigenetic Mechanisms? A Review. Genes, 15(12), 1504. https://doi.org/10.3390/genes15121504
3. Kiani, A. K., Bonetti, G., Donato, K., Kaftalli, J., Herbst, K. L., Stuppia, L., Fioretti, F., Nodari, S., Perrone, M., Chiurazzi, P., Bellinato, F., Gisondi, P., & Bertelli, M. (2022). Polymorphisms, diet and nutrigenomics. Journal of Preventive Medicine and Hygiene, 63(2 Suppl 3), E125–E141. https://doi.org/10.15167/2421-4248/jpmh2022.63.2S3.2754
4. Das, K. C., & Herbert, V. (1976). Vitamin B12—Folate interrelations. Clinics in Haematology, 5(3), 697–745.Vitamin B12--folate interrelations - PubMed
5. Ly, A., Hoyt, L., Crowell, J., & Kim, Y.-I. (2012). Folate and DNA methylation. Antioxidants & Redox Signaling, 17(2), 302–326. https://doi.org/10.1089/ars.2012.4554
6. Lajin, B., Alhaj Sakur, A., Michati, R., & Alachkar, A. (2012). Association between MTHFR C677T and A1298C, and MTRR A66G polymorphisms and susceptibility to schizophrenia in a Syrian study cohort. Asian Journal of Psychiatry, 5(2), 144–149. https://doi.org/10.1016/j.ajp.2012.03.002
7. van der Put, N. M., Gabreëls, F., Stevens, E. M., Smeitink, J. A., Trijbels, F. J., Eskes, T. K., van den Heuvel, L. P., & Blom, H. J. (1998). A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? American Journal of Human Genetics, 62(5), 1044–1051. https://doi.org/10.1086/301825
8. Ménézo, Y., Patrizio, P., Alvarez, S., Amar, E., Brack, M., Brami, C., Chouteau, J., Clement, A., Clement, P., Cohen, M., Cornet, D., Dale, B., D’ Amato, G., Jacquesson-Fournols, L., Mares, P., Neveux, P., Sage, J. C., Servy, E., Huong, T. M., & Viot, G. (2021). MTHFR (methylenetetrahydrofolate reductase: EC 1.5.1.20) SNPs (single-nucleotide polymorphisms) and homocysteine in patients referred for investigation of fertility. Journal of Assisted Reproduction and Genetics, 38(9), 2383–2389. https://doi.org/10.1007/s10815-021-02200-6